Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dreieich – page 69

1 481 clinical trials in Dreieich, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dreieich at a glance
1 481
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 481 trials in Dreieich

Open in trial search

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Pharmacosmos A/S

Atrial fibrillation

Not recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic+1

Not recruiting

Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Glucocorticoids
  • Sponsor:Eli Lilly & Co.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:DC-806
  • Sponsor:DICE Therapeutics Inc.

Study on the Safety and Effectiveness of ESK-001 for Adults with Systemic Lupus Erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

Parkinson's disease

Not recruiting

Study of Suvecaltamide for Treating Moderate to Severe Tremor in Parkinson's Disease Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Suvecaltamide
  • Sponsor:Cavion Inc.

Neurodermatitis

Not recruiting

Study of Rocatinlimab in Adults with Prurigo Nodularis Not Adequately Controlled by Topical Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Arthralgia

Not recruiting

Study on the Effects and Safety of ODM-111 and Paracetamol for Chronic Knee Pain in Osteoarthritis Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ODM-111
  • Sponsor:Orion Corporation

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of Bimekizumab and Risankizumab in Adults with Active Psoriatic Arthritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dreieich

What the registry says about research in the country

01 Allergy Research

Clinical trials focusing on innovative treatments for allergic rhinoconjunctivitis, particularly targeting birch pollen and house dust mite allergies.

  • Birch Pollen Allergies
  • House Dust Mite Sensitivity
  • Immunotherapy Development

Research includes evaluation of subcutaneous immunotherapy treatments and novel allergoid formulations.

02 Pediatric Allergology

Dedicated studies examining the safety and efficacy of STALORAL® treatments in children and adolescents with seasonal allergies.

  • Child-Specific Treatments
  • Age-Appropriate Dosing
  • Safety Monitoring

Special focus on developing safe and effective treatments for young patients aged 5-17 years.

03 Respiratory Medicine

Comprehensive research into moderate to severe allergic conditions affecting the respiratory system, including asthma complications.

  • Combined Symptom Management
  • Therapeutic Efficacy
  • Long-term Treatment Outcomes

Studies evaluate both symptomatic relief and long-term disease modification approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.